MILD 试验:延长肺癌筛查降低 10 年死亡率——肺癌筛查疗效的新证实
MILD 试验将 4099 名参与者随机分为筛查组(n=2376,进一步随机为每年或每两年一次低剂量 CT,中位筛查 6 年)和对照组(n=1723,无干预)。10 年随访显示,筛查组肺癌死亡率风险降低 39%(HR 0.61;95%CI 0.39-0.95),总死亡率降低 20%(HR 0.80;95%CI 0.62-1.03)。5 年后的标志性分析中,肺癌死亡率降低 58%(HR 0.42;95%CI 0.22-0.79),总死亡率降低 32%(HR 0.68;95%CI 0.49-0.94)。
要点
- 10 年随访时,LDCT 筛查组肺癌死亡率风险较对照组降低 39%(HR 0.61;95%CI 0.39-0.95)。
- 10 年总死亡率风险降低 20%(HR 0.80;95%CI 0.62-1.03),未达统计学显著。
- 5 年后筛查获益增强:肺癌死亡率风险降低 58%(HR 0.42;95%CI 0.22-0.79)。
核心结论
- MILD 试验提供额外证据表明,超过 5 年的延长筛查可增强早期发现的获益,与 NLST 试验相比实现更大的总死亡率和肺癌死亡率降低。
研究设计与样本
- 多中心意大利肺癌检测(MILD)试验前瞻性随机纳入 4099 名参与者,筛查组 n=2376,对照组 n=1723(无干预)。
- 筛查组进一步随机为每年一次(n=1190)或每两年一次(n=1186)低剂量 CT,中位筛查期 6 年。
- 2005 年至 2018 年间累计随访 39 293 人年,主要终点为 10 年总死亡率和肺癌特异性死亡率。
- 采用标志性分析排除前 5 年发生的肺癌和死亡,以检验 5 年后筛查的长期效应。
主要发现
- 10 年时,LDCT 筛查组较对照组肺癌死亡率风险降低 39%(HR 0.61;95%CI 0.39-0.95)。
- 10 年时,LDCT 筛查组较对照组总死亡率风险降低 20%(HR 0.80;95%CI 0.62-1.03)。
- 5 年后,LDCT 筛查组较对照组肺癌死亡率风险降低 58%(HR 0.42;95%CI 0.22-0.79)。
- 5 年后,LDCT 筛查组较对照组总死亡率风险降低 32%(HR 0.68;95%CI 0.49-0.94)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The National Lung Screening Trial showed that lung cancer (LC) screening by three annual rounds of low-dose computed tomography (LDCT) reduces LC mortality. We evaluated the benefit of prolonged LDCT screening beyond 5 years, and its impact on overall and LC specific mortality at 10 years. DESIGN: The Multicentric Italian Lung Detection (MILD) trial prospectively randomized 4099 participants, to a screening arm (n = 2376), with further randomization to annual (n = 1190) or biennial (n = 1186) LDCT for a median period of 6 years, or control arm (n = 1723) without intervention. Between 2005 and 2018, 39 293 person-years of follow-up were accumulated. The primary outcomes were 10-year overall and LC specific mortality. Landmark analysis was used to test the long-term effect of LC screening, beyond 5 years by exclusion of LCs and deaths that occurred in the first 5 years. RESULTS: The LDCT arm showed a 39% reduced risk of LC mortality at 10 years [hazard ratio (HR) 0.61; 95% confidence interval (CI) 0.39-0.95], compared with control arm, and a 20% reduction of overall mortality (HR 0.80; 95% CI 0.62-1.03). LDCT benefit improved beyond the 5th year of screening, with a 58% reduced risk of LC mortality (HR 0.42; 95% CI 0.22-0.79), and 32% reduction of overall mortality (HR 0.68; 95% CI 0.49-0.94). CONCLUSIONS: The MILD trial provides additional evidence that prolonged screening beyond 5 years can enhance the benefit of early detection and achieve a greater overall and LC mortality reduction compared with NLST trial. CLINICALTRIALS.GOV IDENTIFIER: NCT02837809.
引用
- Pastorino U, Silva M, Sestini S, et al. Prolonged lung cancer screening reduced 10-year mortality in the MILD trial: new confirmation of lung cancer screening efficacy. Ann Oncol. 2019. PMID: 30937431. doi:10.1093/annonc/mdz117
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。